Side Effects of Bosutinib

Common side effects in these studies included nausea, vomiting and diarrhea, which diminished over time. Lowered numbers of other blood cells, including platelets, white and red blood cells, were seen in one percent to nine percent of patients. There was also a buildup of fluid in the lungs and organs of 12 patients. But all of these symptoms were less severe than with other tyrosine kinase inhibitors.

A clinical trial just finishing in June of 2008 attempted to determine if bosutinib would be useful as therapy in advanced and metastatic breast cancer. This study included participants in the United States, China, France, Ireland, Italy, Malta, Poland, the Russian Federation, the Ukraine, and the United Kingdom. The results of this study are not available.

Another trial is finishing which evaluated the safety and efficacy of bosutinib for advanced or recurrent solid malignancies for which no other effective treatment was available. Participants in this trial were across the United States. Results have not yet been published.